LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dietary Pill Could Reduce Fat and Sugar in Food

By LabMedica International staff writers
Posted on 07 Jun 2011
Print article
A new nanocomplex dietary supplement that can be taken before meals could substantially reduce the amount of fat and sugar absorbed.

Researchers at Hebrew University (Jerusalem, Israel) and Harvard University (Boston, MA, USA) developed the nanocomplex based on naringenin, a flavonoid aglycone responsible for the bitter taste in grapefruit, which is poorly absorbed by the body when in its natural form. To overcome this problem, the solubility of naringenin was enhanced by complexation with Hydroxypropoyl-β-cyclodextrin (HPβCD), which increased the solubility of naringenin by over 400-fold, and its transport across a model of the gut epithelium by 11-fold. As an added benefit, when the molecule is turned into cyclodextrin, it becomes sweet; thus, naringenin is no longer bitter.

The researchers then tested the product on rats, and found that the nanocomplex increased naringenin plasma concentrations values by 7.4-fold. Moreover, when the complex was administered just prior to a meal, it decreased very low-density lipoprotein (VLDL) levels by 42% and increased the rate of glucose clearance by 64%, compared to naringenin alone. Histology and blood chemistry analysis indicated this route of administration was not associated with damage to the intestine, kidney, or liver. According to the researchers, these results suggest that the complexation of naringenin with HPβCD is a viable option for the oral delivery of naringenin as a therapeutic entity with applications in the treatment of dyslipidemia, diabetes, and hepatitis c virus (HCV) infection. The study was published in the April 6, 2011, issue of PLoS One.

"The complex is special in that it is taken just before a meal as a preventative measure," said lead author Yaakov Nahmias, PhD, of the Hebrew University School of Engineering and Computer Science. "In comparison, existing medications are given only after chronic development of abnormal lipid levels in the blood."

Related Links:
Hebrew University
Harvard University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more